Drug Trial Radar · NCT07658534
A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.
Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
290
Planned (sponsor's estimate)
Start
Mar 3, 2026
Primary completion
Dec 2028
Study completion Jan 2029
Sponsor
- Lead sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Respiratory syncytial virus (RSV) is recognized worldwide as a significant pathogen causing lower respiratory tract infection in infants, the elderly, and immunocompromised patients, which may cause bronchiolitis or pneumonia, and affect the cardiovascular system, central nervous system and the renal system, resulting in hospitalization and death risks in children and also high-risk adults, particularly the elderly. The purpose of this study is to evaluate the efficacy of Ziresovir (AK0529) compared to placebo with respect to the time to resolution of RSV lower respiratory tract disease (LRTD) symptoms.
Conditions
- Respiratory Syncytial Virus Infections
Interventions
Ziresovir (AK0529)Drug
Active Substance: AK0529 Pharmaceutical Form: Enteric Capsules Route of Administration: Oral
PlaceboDrug
Active Substance: Placebo Pharmaceutical Form: Enteric Capsules Route of Administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time from first dose to resolution of LRTD symptomsTime frame: Up to Day 27
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China · Recruiting
Guangzhou Medical University Panyu Central Hospital
Guangzhou, Guangdong, China · Not yet recruiting
Cangzhou Hospital of Integrated TCM-WM
Cangzhou, Hebei, China · Recruiting
The First Affiliated Hospital of Nanyang Medical College
Nanyang, Henan, China · Recruiting
Henan Infectious Disease Hospital (The Sixth People's Hospital of Zhengzhou)
Zhengzhou, Henan, China · Not yet recruiting
Wuhan Sixth Hospital
Wuhan, Hubei, China · Recruiting
Zhejiang Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
People's Hospital of Rui'an City
Rui’an, Zhejiang, China · Recruiting
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.